Understanding the Market | JENSCARE-B rises over 6% as its subsidiary Ken-Valve successfully completes the first batch of commercial implants recently
I'm PortAI, I can summarize articles.
JENSCARE-B's stock price rose over 6% again, up 4.45% as of the time of writing, priced at HKD 8.92, with a transaction volume of HKD 3.7648 million. The company's core product, Ken-Valve, has successfully completed its first batch of commercial implants, marking the start of its commercialization in China. This product has garnered expert attention at the West China Minimally Invasive Cardiovascular Conference. In the future, the company will expand its sales network, advance the global commercialization process, and optimize production costs to achieve revenue targets
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments